[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
February 26, 2001

Should New Drugs Be Used Without Outcome Data?Implications of ALLHAT and ELITE II

Arch Intern Med. 2001;161(4):511-512. doi:10.1001/archinte.161.4.511

AS THE most common disease encountered by medical practitioners, hypertension continues to attract new therapies that promise greater efficacy and fewer adverse effects than currently available drugs. The most recently introduced new class of antihypertensive drugs, the angiotensin II receptor blockers (ARBs), is the fastest-growing group, having been prescribed in the United States more than 23 million times in 1999, only a few years after their introduction. With 6 ARBs now available, and more likely on the way, they are widely touted as a major advance, in part because of their tolerability.1,2

First Page Preview View Large
First page PDF preview
First page PDF preview
×